



UNIVERSITY OF LEEDS

This is a repository copy of *Satisfaction, adherence and health-related quality of life with transdermal buprenorphine compared with oral opioid medications in the usual care of osteoarthritis pain*.

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/102686/>

Version: Supplemental Material

Article:

Conaghan, P, Serpell, M, McSkimming, P et al. (2 more authors) (2016) Satisfaction, adherence and health-related quality of life with transdermal buprenorphine compared with oral opioid medications in the usual care of osteoarthritis pain. *The Patient: Patient-Centered Outcomes Research*, 9 (4). pp. 359-371. ISSN 1178-1653

<https://doi.org/10.1007/s40271-016-0181-0>

Reuse

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Table A.**Number of oral medications taken in addition to the target medication**

Number of oral medicines	All		One target		TDB		Co-codamol		Tramadol	
	N = 966	n (%)	N = 701	n (%)	N = 85	n (%)	N = 373	n (%)	N = 243	n (%)
1-3	273	(28.3)	223	(31.8)	32	(37.6)	129	(34.6)	62	(25.5)
4-5	329	(34.1)	253	(36.1)	34	(40.0)	146	(39.1)	73	(30.0)
6-7	103	(10.7)	69	(9.8)	10	(11.8)	26	(7.0)	33	(13.6)
8-9	84	(8.7)	57	(8.1)	3	(3.5)	30	(8.0)	24	(9.9)
10 or more	177	(18.3)	99	(14.1)	6	(7.1)	42	(11.3)	51	(21.0)

Table B.**Adherence results for each question of the Morisky Medication Adherence Scale**

Scores recorded at baseline, showing numbers for the ‘high adherence’ answer in each case. Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A Licensure agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, Professor, Department of Community Health Sciences, UCLA School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1772, dmorisky@ucla.edu.

		Analysis population	One target	TDB	Co-codamol	Tramadol
		N = 966 n (%)	N = 701 n (%)	N = 85 n (%)	N = 373 n (%)	N = 243 n (%)
Q1: Do you sometimes forget to take your OA pain medication(s)?	No	618 (64.0)	454 (64.8)	53 (62.4)	239 (64.1)	162 (66.7)
Q2: People sometimes miss taking their medications for reasons other than forgetting. Thinking over the past 2 weeks, were there any days when you did not take you OA pain medication(s)?	No	644 (66.7)	465 (66.3)	70 (82.4)	233 (62.5)	162 (66.7)
Q3: Have you ever cut back or stopped taking your OA medication(s) without telling your doctor, because you felt worse when you took it?	No	659 (68.3)	479 (68.3)	58 (68.2)	243 (65.1)	178 (73.3)
Q4: When you travel or leave home, do you sometimes forget to bring along your OA medications(s)?	No	714 (74.0)	520 (74.2)	71 (83.5)	259 (69.4)	190 (78.2)
Q5: Did you take/wear your OA pain medication(s) yesterday?	Yes	803 (83.2)	565 (80.6)	59 (69.4)	301 (80.7)	205 (84.4)
Q6: When you feel like your OA pain is under control, do you sometimes stop taking your medication(s)?	No	618 (64.0)	434 (61.9)	68 (80.0)	194 (52.0)	172 (70.8)
Q7: Taking medication(s) every day is a real inconvenience for some people. Do you ever feel hassled about sticking to your OA pain treatment plan?	No	522 (54.1)	393 (56.1)	62 (72.9)	192 (51.5)	139 (57.2)
Q8: How often do you have difficulty remembering to take all your medication(s)?	Never/ rarely	417 (43.2)	303 (43.2)	45 (52.9)	158 (42.4)	100 (41.2)

Table C.**Reasons for discontinuation**

Reasons for discontinuation after Months 1, 2 and 3 (full analysis population; this table includes patients who were in single treatment groups at each follow up, which may be different from their treatment group at baseline).

		TDB			Co-codamol			Tramadol		
		Month 1 (N = 35)	Month 2 (N = 17)	Month 3 (N = 11)	Month 1 (N = 203)	Month 2 (N = 149)	Month 3 (N = 130)	Month 1 (N = 145)	Month 2 (N = 116)	Month 3 (N = 104)
Patients who changed treatment group	Yes	6 (17.1%)	2 (11.8%)	1 (9.1%)	13 (6.4%)	5 (3.4%)	7 (5.4%)	9 (6.2%)	7 (6.0%)	11 (10.6%)
	No	29 (82.9%)	15 (88.2%)	10 (90.9%)	190 (93.6%)	144 (96.6%)	123 (94.6%)	136 (93.8%)	109 (94.0%)	93 (89.4%)
Reasons for discontinuation	n (missing)	6 (29)	2 (15)	1 (10)	12 (191)	5 (144)	7 (123)	8 (137)	7 (109)	11 (93)
	Side-effects experienced specifically due to your medication	0 (0.0%)	0 (0.0%)	1 (100.0%)	5 (41.7%)	2 (40.0%)	1 (14.3%)	0 (0.0%)	4 (57.1%)	2 (18.2%)
	Felt better/didn't feel the need for it	2 (33.3%)	0 (0.0%)	0 (0.0%)	1 (8.3%)	0 (0.0%)	3 (42.9%)	0 (0.0%)	0 (0.0%)	4 (36.4%)
	Wasn't working/lack of effect	2 (33.3%)	1 (50.0%)	0 (0.0%)	3 (25.0%)	0 (0.0%)	1 (14.3%)	3 (37.5%)	1 (14.3%)	1 (9.1%)
	Wanted to reduce tablet burden	1 (16.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (40.0%)	1 (14.3%)	1 (12.5%)	0 (0.0%)	0 (0.0%)
	Complicated dosing regimen	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Other	1 (16.7%)	1 (50.0%)	0 (0.0%)	1 (8.3%)	0 (0.0%)	0 (0.0%)	1 (12.5%)	1 (14.3%)	3 (27.3%)
	Not provided	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (16.7%)	1 (20.0%)	1 (14.3%)	3 (37.5%)	1 (14.3%)	1 (9.1%)

Table D.**Adverse events reported**

Events with an incidence $\geq 10\%$ at system organ class level, or $\geq 5\%$ at preferred term level are included.

System organ class is listed alphabetically and MedDRA term is listed in descending frequency within each system organ class.

System Organ Class MedRA Preferred Term	One target (N = 701) n (%)	TDB (N = 85) n (%)	Co-codamol (N = 373) n (%)	Tramadol (N = 243) n (%)
Any adverse event	359 (51.2)	26 (30.6)	199 (53.4)	134 (55.1)
Gastrointestinal Disorders	195 (27.8)	15 (17.6)	129 (34.6)	51 (21)
Constipation	122 (17.4)	8 (9.4)	89 (23.9)	25 (10.3)
Nausea	40 (5.7)	3 (3.5)	27 (7.2)	10 (4.1)
General disorders and administration site conditions	150 (21.4)	14 (16.5)	69 (18.5)	67 (27.6)
Fatigue	40 (5.7)	5 (5.9)	16 (4.3)	19 (7.8)
Malaise	41 (5.8)	3 (3.5)	21 (5.6)	17 (7.0)
Nervous System Disorders	148 (21.1)	6 (7.1)	76 (20.4)	66 (27.2)
Dizziness	56 (8.0)	5 (5.9)	25 (6.7)	26 (10.7)
Somnolence	79 (11.3)	1 (1.2)	42 (11.3)	36 (14.8)
Psychiatric Disorders	45 (6.4)	1 (1.2)	17 (4.6)	27 (11.1)
Insomnia	17 (2.4)	1 (1.2)	3 (0.8)	13 (5.3)

Satisfaction, adherence and health-related quality of life with transdermal buprenorphine compared with oral opioid medications in the usual care of osteoarthritis pain. The Patient. Conaghan PG,¹ Serpell M,² McSkimming P,³ Junor R,⁴ Dickerson S⁴

1. Leeds Institute of Rheumatic and Musculoskeletal Medicine and National Institute of Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, University of Leeds, UK; 2. University Department of Anaesthesia, Gartnavel General Hospital, Glasgow, UK; 3. Robertson Centre for Biostatistics, University of Glasgow, UK; 4. Napp Pharmaceuticals Limited, Cambridge, UK

Corresponding author: Sara Dickerson – Sara.Dickerson@mundipharma.co.uk